Verséa Ophthalmics Commences Phase 1 Launch of Novel Tear-based Point-of-Care (T-POC) Quantitative Testing Platform
TAMPA, Fla.--(BUSINESS WIRE)-- #DED--Verséa™ Ophthalmics, LLC, a division of Verséa Health, Inc. committed to delivering novel, high-value diagnostic and therapeutic solutions to improve ocular disease, proudly announces the commencement of initial shipments of its T-POC TOTAL IgE Immunoassay and Lateral Flow Readers. The company focuses on delivering innovative Tear-based Point-of-Care (T-POC) testing and biologic solutions that optimize diagnosis, treatment, and management of various eye care condit